Increased Antipsychotic Sensitivity in Elderly Patients: Evidence and Mechanisms
Hiroyuki Uchida, David C Mamo, Benoit H Mulsant, Bruce G Pollock, Shitij Kapur
The Journal of Clinical Psychiatry | PHYSICIANS POSTGRADUATE PRESS | Published : 2009
Awarded by National Institute of Mental Health
Financial disclosure: Dr. Uchida has received fellowship support from the Japanese Society of Clinical Neuropsychopharmacology, Pfizer Health Research Foundation, and Mochida Memorial Foundalion; has received manuscript fees from Otsuka and Dainippon Sumitomo Pharma; and has received speaker's honoraria from GlaxoSmithKline and Janssen within the past 5 years. Dr. Mamo has received grants, consultant fees, or other financial support from the Canadian Psychiatric Research Foundation, Schizophrenia Society of Canada, Stanley Medical Research Institute, and Bristol-Myers Squibb and has received speaker's honoraria from AstraZeneca within the past 5 years. Dr. Mulsant holds stock in Akzo-Nobel, Alkermes, AstraZeneca, Biogen Idec, Celsion, Elan, Eli Lilly, Forest, General Electric, Immune Response, and Pfizer; has received grants, consultant fees, or other financial support from the National Institutes of Health, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest, Fox Learning System, GlaxoSmithKline, Janssen, Lundbeck, and Pfizer within the past 3 years and hits been a member of the speakers' bureaus of AstraZeneca, Eisai, Forest, GlaxoSmithKline, and Pfizer within the past 5 years. Dr. Pollock has received grant/research support from the National Institutes of Health and Janssen, has served on the advisory board of Forest, is a faculty member of the Lundbeck Institute, and is on the speakers' bureau of Forest and Lundbeck. Dr. Kapur has received grant support front AstraZeneca, Bristol-Myers Squibb, Eli Lilly, EMD-Darmstadt, GlaxoSmithKline, Janssen, Neuromolecular Inc., and Pfizer and has served as a consultant, scientific advisor, or speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Otsuka, Organon, Pfizer, Sanofi-Synthelabo, Servier, and Solvay-Wyeth within the past 5 years.This study was supported by National Institute of Mental Health grants MH065416 and MH064173, the Sandra A. Rotman Chair in Neuropsychiatry, and a Canada Research Chair grant (Dr. Pollock) and the Japanese Society of Clinical Neuropsychopharmacology and the Mochida Memorial Foundation (Dr. Uchida).